Navigation Links
Senesco Chooses VGXI to Produce Factor 5A Plasmid
Date:7/3/2008

NEW BRUNSWICK, N.J., July 3 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT) announced today that it has contracted with VGXI, Inc. (The Woodlands, TX) ("VGXI") to supply the plasmid portion of the Company's combination therapy consisting of the Factor 5A gene and siRNA against Factor 5A.

Senesco has previously reported positive preclinical in vivo results using its combination siRNA and plasmid against subcutaneous multiple myeloma tumors in immunodeficient mice. The Factor 5A plasmid being produced by VGXI, as Senesco's preclinical data has shown, should cause cancer cells to enter apoptosis, or programmed cell death.

"VGXI's manufacturing and technical expertise in producing plasmids for Senesco's planned toxicology study and ultimately our clinical trial led us to choose them. We are pleased to be working with a company that has such an outstanding reputation in the field," commented Bruce Galton, Senesco's President and CEO.

Henry Hebel, Vice President of Operations for VGXI said, "We believe that our ability to quickly supply the preclinical and clinical needs of our clients will allow Senesco to rapidly advance their programs. We are continuing to expand our collaborative development services to meet the growing needs for a wide variety of plasmid based products."

About VGXI Inc.

VGXI Inc. is a leading manufacturer of DNA plasmids, and its cGMP and non-cGMP products have passed rigorous reviews by several international regulatory agencies. VGXI offers a wide variety of contract manufacturing services to outside client organizations. The Company's cGMP manufacturing facility in The Woodlands, Texas is a flexible, purpose-built facility used for research,
'/>"/>

SOURCE Senesco Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
2. Senescos Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences
3. Senesco Technologies Initiates Preclinical Studies for Cancer Target
4. OncoMed Chooses SynCo Bio Partners to Fill and Finish its Lead Antibody
5. Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
6. Infant Vaccines Produce Autism Symptoms in New Primate Study by University of Pittsburgh Scientists
7. New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
8. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
9. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
10. R-CALF United Stockgrowers of America: Fighting for the U.S. Cattle Producer
11. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Edwards Lifesciences Corporation (NYSE: EW ), the ... monitoring, today announced that Robert A. Ingram has ... is an ardent champion for innovation in the lifesciences industry, ... on Edwards, board as we pursue our focused innovation strategy," ... "Bob has provided a valuable perspective to our board, drawing ...
(Date:7/30/2015)... 30, 2015  ResMed Inc. (NYSE: RMD ) ... 2015.  Revenue for the quarter was $453.1 million, a ... 30, 2014 (a 17 percent increase on a constant ... the quarter ended June 30, 2014.  Diluted earnings per ... quarter ended June 30, 2014.  The ...
(Date:7/30/2015)... , July 30, 2015  Unichem Pharmaceuticals ( ... one lot of Hydrochlorothiazide tablets 25 mg 1000-count bottle ... as a precautionary measure due to the identification of ... product. The risk associated with mistakenly ... is the increased probability of experiencing Clopidogrel,s side effects ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2
... Pilot Study Demonstrates 50% ... ANNAPOLIS, Md., March 29, 2007,/PRNewswire-FirstCall/ -- Medarex, Inc. ... a privately held,biotechnology company dedicated to the development ... human,monoclonal antibody product candidate being developed for the,prevention ...
... DIEGO--(BUSINESS WIRE)--Mar 29, 2007 - ACADIA Pharmaceuticals,Inc. ... to fuel drug discovery and clinical,development of ... announced that the company will present at ... from,March 28 through April 1, 2007, in ...
Cached Medicine Technology:Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 2Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 3Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 4Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 5Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 6Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 7Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 8ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 2ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 3ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 4ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 5
(Date:7/31/2015)... York (PRWEB) , ... July ... ... attorney Jason T. Brown’s live lecture on pharmaceutical negligence is now available ... 2015 was well received with a 94% approval rating from the nationwide ...
(Date:7/31/2015)... ... July 31, 2015 , ... As part of their ... involvement and support of animal welfare organizations is essential to the longevity of their ... year in the National Association of Professional Pet Sitters (NAPPS) annual Presents 4 Pets ...
(Date:7/31/2015)... ... ... Transfinder, a software company based in Schenectady, N.Y., achieved record revenue for ... the first six months ended June 30, 2015 compared with the same period in ... record-revenue mark of $10.4 million. , “We know what our customers need and want ...
(Date:7/31/2015)... ... July 31, 2015 , ... “Engage: Don’t ... the industry’s premier thought leadership symposiums, hosted by Massachusetts-based Harmony Healthcare International ... event attracts over 250 “C”-level executives, administrators, directors of nursing, rehabilitation managers and ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... firm, has been recognized in the 2015 Aster Awards national competition for a ... organization serving Ocean City and surrounding communities in Coastal Maryland and Southern Delaware. ...
Breaking Medicine News(10 mins):Health News:Re-Broadcast of Nationally Renowned Trial Attorney Jason T. Brown's Lecture on Pharmaceutical Negligence Now Available 2Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 2Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 3Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 4Health News:Transfinder Closes First Half of 2015 with Record Revenue 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 3Health News:Mullin/Ashley Associates Wins in the 2015 Aster Awards National Competition for Excellence in Medical Marketing 2
... Dinoire’s countenance has changed 360 degrees in comparison to how ... the first patient in the world to undergo a// partial ... year ago, combined the dexterity of a 50 member team, ... has recovered very well. ,Miss Dinoire, 39, ...
... Maldives men's volleyball team lost to Chinese Taipei (Taiwan) in ... three of its players were confirmed to have chicken// pox. ... Asian Volleyball Confederation (AVC) said in a statement. ... pox. The disease spreads easily and we have to make ...
... in Mumbai suffers from backache, caused mainly by the poor ... out by Health India, a New Delhi-based non-profit group, the ... Delhi and 77 percent in Mumbai who use public transport ... ,"Bad roads, overcrowded public transport systems, poor quality of ...
... revealed that first time ecstasy users may suffer impaired memory and ... areas of the brain. , ,'We do not know if ... the University of Amsterdam, who led the study. 'Therefore, we cannot ... brain, and people should be informed of this risk.' ...
... the United Kingdom concluded that the UK's National Health ... least// for now. The review was published in the ... series of the Health Technology Assessment Programme, part of ... Kingdom. ,An implantable pump can help heart ...
... you hate being told to sit upright by others, because ... indeed what suits your// body better. Sitting ramrod straight may ... team of Scottish radiologists presented their findings recently at Chicago.They ... monitored using a specialized MRI scanner that could record their ...
Cached Medicine News:Health News:Maldives Volleyball Team Members Affected by Chickenpox 2Health News:Public Transport Causing Backaches in Delhi, Mumbai 2Health News:Review Urges Restricted Use Of Devices To Keep Heart Patients Alive 2Health News:Review Urges Restricted Use Of Devices To Keep Heart Patients Alive 3
... IMMULITE 2500 is a high-throughput immunoassay ... ,of the IMMULITE 2000 with the important ... technology ,allows assays to be designed for ... times. ,This allows for critical assays such ...
... sulfate (DHEA-S) is the sulfate ester of ... enzymatic conversion of DHEA in adrenal and ... steroid secreted by the adrenal cortex, and ... biosynthesis. DHEA possesses relatively weak androgenic activity, ...
... DSL's unique DHEA-S-7kits ... antiserum targeted against the ... DHEA-S molecule, with no ... DHEA-S Saliva RIA has ...
... is based on the competition principle and ... DHEA-S present in the sample and a ... peroxidase compete for the binding sites of ... wells. After one hour incubation the microtiterplate ...
Medicine Products: